India's Stempeutics seeks partner as projects advance
This article was originally published in Scrip
Stempeutics Research, an Indian stem cell company, is hoping to rope in a strategic partner to finance its R&D, even as it remains upbeat about the prospects of ongoing trials to develop potential treatments for acute myocardial infarction and critical limb ischaemia.
You may also be interested in...
Wockhardt has received approvals in India for two novel broad spectrum antibiotics with "advantageous" safety features over older MRSA drugs and the firm hopes to take them to other emerging markets as well, with China on the radar.
2019 saw Indian companies advance innovation efforts and build and expand their specialty portfolios and biosimilars businesses. But manufacturing compliance issues weighed down several firms while on another front charges against the Singh brothers of Ranbaxy escalated.
Glenmark is working on a combination of remogliflozin and teneligliptin in India, which if successful could bring additional sting to its portfolio in the country's bustling diabetes segment. But Boehringer-Lilly’s rival Glyxambi already has a head-start.